Physician

Rita Gupta, M.D.

According to 2025 Medicare claims, Rita Gupta, M.D. (NPI: 1003857269) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from Prince Georges, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY, P.A. (NPI: 1821271032; TIN: 113652573) and primary practice location at 20613-3045.

Gupta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,069 traditional Medicare patients, billed 186,065 HCPCS/CPT codes, and received $2,905,012 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,190 prescription claims across 256 beneficiaries totaling $2,222,397 in drug costs, led by Revlimid (Lenalidomide). DME data shows 54 claims. Open Payments data shows 117 records totaling $2,855. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,297,134 to $2,905,012. Similarly, Part D prescription costs have risen steadily, from $160,339 to $2,222,397. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	773	158,116	$1,297,134
2016	770	147,693	$1,452,074
2017	853	164,949	$1,776,684
2018	902	227,104	$2,710,340
2019	882	273,687	$3,015,902
2020	868	329,898	$4,040,430
2021	922	374,984	$3,625,343
2022	1,027	326,814	$2,927,648
2023	1,049	300,494	$3,056,379
2024	1,069	186,065	$2,905,012

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	100	362	$160,339
2016	118	505	$116,154
2017	104	562	$304,515
2018	138	796	$547,895
2019	131	820	$950,278
2020	150	754	$749,457
2021	154	859	$1,090,654
2022	168	889	$1,727,426
2023	187	842	$1,402,682
2024	256	1,190	$2,222,397

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$1,223
2016	N/R	68	$14,898
2017	11	13	$1,377
2018	N/R	11	$943
2019	11	54	$5,491
2020	12	75	$5,126
2021	11	99	$6,044
2022	N/R	94	$3,218
2023	N/R	62	$11,457
2024	N/R	54	$989

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	547	1,199	$112
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	392	616	$78
80053	Blood test, comprehensive group of blood chemicals	615	2,069	$10
36415	Insertion of needle into vein for collection of blood sample	291	543	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	616	2,548	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	20	560	$309,097
Lenalidomide	Lenalidomide	19	532	$308,191
Tukysa	Tucatinib	12	360	$308,175
Verzenio	Abemaciclib	13	364	$199,701
Jakafi	Ruxolitinib Phosphate	24	720	$164,516

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	25	$538
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$301
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	117	$2,855	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rita Gupta, M.D.?

Tedicare shows public-source Medicare data for Rita Gupta, M.D. (NPI 1003857269), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rita Gupta, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rita Gupta, M.D.?

Rita Gupta, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY, P.A. (billing NPI 1821271032) in the available physician profile data.

Does Rita Gupta, M.D. have Open Payments data?

Rita Gupta, M.D. has 117 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.